; The Behavioral Measurement Shared Resource (BMSR) provides expert assistance and services for integrating behavioral research into the research goals of the OSUCCC. Since its inaugural year in 2004, there has been a greater than 12-fold increase in usage: in 2009, nearly 20,000 hours of service was provided and 93.36% of that usage came from funded OSUCCC members. This increase in usage is expected to continue. The BMSR is directed by Dr. Michael Slater with assistance from six senior staff and strong institutional support. Together, they provide leadership and coordination of the Shared Resource to enhance high quality cancer relevant investigations.
The specific aims of the BMSR are to: 1. Support prevention and control researchers by providing population-based data retrieval, consultation for patient accrual procedures and locations, identifying or adapting existing measures of key behavioral constructs and guidance or assistance with behavioral data collection methodology and/or personnel; 2. Provide any OSUCCC investigator with this support as well as research design expertise for the incorporation of behavioral aims within any basic or clinical cancer research project. Specifically, the BMSR supports the following services within peer-reviewed funded research: 1) research design;2) population-based data retrieval;3) recruitment and accrual, particularly with under served and minority populations;4) behavioral assessment;and 5) data collection. The availability of design and behavioral measurement consultations enables investigators to reduce time for project development and speed the research process. To enhance National Cancer Institute and OSUCCC goals to support outstanding population science research projects, the BMSR services ensure the inclusion of: research participants that are broadly representative of the target population(s);behavioral constructs that are theoretically and empirically supported;behavioral measures that are psychometrically sound;standardized assessment procedures for reliable data collection and management and expertise for consultation regarding analysis of behavioral data. Thus, the BMSR provides a continuum of services, ranging from planning for and developing research proposals and projects, through data collection and the interpretation of behavioral data. OSUCCC members with peer-reviewed funding account for 93.36 % of the total usage and is derived from five of the six OSUCCC scientific programs including Cancer Control (CC), Innate Immunity (IMM), Molecular Biology and Cancer Genetics (MBCG) and Molecular Carcinogenesis and Chemoprevention (MCC).

Public Health Relevance

; BMSR provides OSUCCC investigators with capability to develop proposals and execute high-quality, sophisticated behavioral research. Services range from intensive recruitment and data collection in hard-to reach populations that may involve thousands of participants, to providing young investigators and clinical researchers with occasional behavior research needs through assistance with design, measurement, recruitment and data collection at a level of expertise that would otherwise be unavailable to them.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016058-38
Application #
8601808
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2013-12-01
Budget End
2014-11-30
Support Year
38
Fiscal Year
2014
Total Cost
$150,590
Indirect Cost
$51,843
Name
Ohio State University
Department
Type
DUNS #
832127323
City
Columbus
State
OH
Country
United States
Zip Code
43210
Kim, So-Youn; Nair, Devi M; Romero, Megan et al. (2018) Transient inhibition of p53 homologs protects ovarian function from two distinct apoptotic pathways triggered by anticancer therapies. Cell Death Differ :
Yadav, Marshleen; Song, Feifei; Huang, Jason et al. (2018) Ocimum flavone Orientin as a countermeasure for thrombocytopenia. Sci Rep 8:5075
Siegel, Marni B; He, Xiaping; Hoadley, Katherine A et al. (2018) Integrated RNA and DNA sequencing reveals early drivers of metastatic breast cancer. J Clin Invest 128:1371-1383
White, Brian S; Lanc, Irena; O'Neal, Julie et al. (2018) A multiple myeloma-specific capture sequencing platform discovers novel translocations and frequent, risk-associated point mutations in IGLL5. Blood Cancer J 8:35
Owen, Dwight; Chaft, Jamie E (2018) Immunotherapy in surgically resectable non-small cell lung cancer. J Thorac Dis 10:S404-S411
O'Brien, Susan M; Jaglowski, Samantha; Byrd, John C et al. (2018) Prognostic Factors for Complete Response to Ibrutinib in Patients With Chronic Lymphocytic Leukemia: A Pooled Analysis of 2 Clinical Trials. JAMA Oncol 4:712-716
Guo, Sijin; Piao, Xijun; Li, Hui et al. (2018) Methods for construction and characterization of simple or special multifunctional RNA nanoparticles based on the 3WJ of phi29 DNA packaging motor. Methods 143:121-133
Sadowski, Abbey R; Gardner, Heather L; Borgatti, Antonella et al. (2018) Phase II study of the oral selective inhibitor of nuclear export (SINE) KPT-335 (verdinexor) in dogs with lymphoma. BMC Vet Res 14:250
Barredo, Julio C; Hastings, Caroline; Lu, Xiamin et al. (2018) Isolated late testicular relapse of B-cell acute lymphoblastic leukemia treated with intensive systemic chemotherapy and response-based testicular radiation: A Children's Oncology Group study. Pediatr Blood Cancer 65:e26928
Reinbolt, Raquel E; Sonis, Stephen; Timmers, Cynthia D et al. (2018) Genomic risk prediction of aromatase inhibitor-related arthralgia in patients with breast cancer using a novel machine-learning algorithm. Cancer Med 7:240-253

Showing the most recent 10 out of 2602 publications